Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624090 | 0.81 | CA12 (0.53) | PTPN1PTPN6PTPN11TRPA1CYP3A4 | |
| Benzene SCHEMBL4222994 | 0.78 | CA12 (0.50) | PTPN1PTPN6PTPN11RAB9ANPC1 | |
| SCHEMBL8778642 | 0.77 | PTPN1 (0.55) | PTPN1PTPN6PTPN11RAB9ANPC1 | |
| SCHEMBL1243626 | 0.77 | ESR1 (0.50) | CYP3A4MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL6545751 | 0.77 | CYP3A4 (0.51) | PTPN1PTPN6PTPN11RAB9ANPC1 | |
| SCHEMBL9496835 | 0.75 | ESR1 (0.58) | RAB9ANPC1CYP3A4MAPTCYP1A2 | |
| SCHEMBL27522483 | 0.75 | TDP1 (0.44) | PTPN1PTPN6PTPN11RAB9ANPC1 | |
| SCHEMBL7869320 | 0.75 | KMT2A (0.66) | RAB9ANPC1MAPTGPR52MEN1 | |
| SCHEMBL7755245 | 0.75 | TDP1 (0.44) | PTPN1PTPN6PTPN11RAB9ANPC1 | |
| SCHEMBL18668866 | 0.75 | TDP1 (0.49) | PTPN1PTPN6PTPN11RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | GUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-1402895-A1 | Benzimidazole inhibitors of fructose 1,6-biphosphatase | Metabasis Therapeutics, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-0970095-B1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6399782-B1 | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| US-6110903-A | INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE AT THE AMP SITE; ADMINISTERING TO TREAT DIABETES AND INHIBIT GLUCONEOGENESIS; 5-FLUORO-7-BROMO-1-ISOBUTYL-2-(2-PHOSPHONO-5-FURANYL) BENZIMIDAZOLE, FOR EXAMPLE | SANKYO COMPANY LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0970095-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039343-A9 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039343-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024516-A1 | ISOQUINOLINONE DERIVATIVES SERVING AS ROCK PROTEIN KINASE INHIBITORS AND USE THEREOF | ROCK1, ROCK2, CIT | PTPN1 1546/4885PTPN6 2053/4885PTPN11 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.